AbbVie's ABBV-295 Obesity Data Opens New Non Incretin Opportunity [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. AbbVie (NYSE:ABBV) reported positive topline Phase 1 results for ABBV-295, a long-acting amylin analog for obesity treatment. The trial showed meaningful, dose-dependent reductions in body weight, signaling potential clinical relevance in obesity care. ABBV-295 uses a non-incretin mechanism of action, setting it apart from widely discussed GLP-1 and GIP agonists. The readout marks AbbVie's entry into the competitive anti-obesity drug market and supports its aim to diversify beyond immunology. AbbVie, best known for its immunology and oncology franchise, is now stepping into obesity therapeutics with ABBV-295. The Phase 1 data arrives at a time when obesity drugs are a key focus for healthcare investors and large pharmaceutical groups, with attention on differentiated mechanisms that sit alongside GLP-1 and GIP drugs. For you as an investor, ABBV-295 adds another angle to the NYSE:ABBV
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- 2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory [Yahoo! Finance]Yahoo! Finance
- 2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- What You Need to Know Ahead of AbbVie's Earnings Release [Yahoo! Finance]Yahoo! Finance
- Assessing AbbVie (ABBV) Valuation After New Dermatology Data And FDA Label Update [Yahoo! Finance]Yahoo! Finance
- Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting® [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- ABBV's page on the SEC website